ClinicalTrials.gg

Program

rovatirelin

Also written as “KPS-0373”, “KPS-0373, High dose” and “KPS-0373, Low dose”.

Its studies are mostly in Spinocerebellar Degenerations, led by Kissei Pharmaceutical.

Furthest: phase 3, since Oct 22, 20139 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceutical91 open or runningphase 3since Oct 22, 2013Mar 16, 2009Mar 31, 2027phase 3 · NCT07040137

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2009First study: phase 2 study in Spinocerebellar DegenerationsFirst studyNCT00863538 · 40 enrolled · Japan
  2. Oct 27, 2009Phase 2 study in Spinocerebellar DegenerationsNCT01004016 · 20 enrolled · Japan
  3. Jun 23, 2011Phase 2 study in Spinocerebellar DegenerationsNCT01384435 · 200 enrolled · Japan
  4. Oct 22, 20134 phase 3 studies in Spinocerebellar DegenerationsNCT01970137, NCT01970124, NCT01970111 and 1 more
  5. Aug 31, 2016Phase 3 study in Spinocerebellar DegenerationsNCT02889302 · 203 enrolled · Japan
  6. Jun 25, 2025Phase 3 study in Spinocerebellar DegenerationsNCT07040137 · 142 enrolled · Japan

Ahead

  1. Mar 31, 2027Primary completion: phase 3 study in Spinocerebellar DegenerationsNCT07040137

TargetBeta

TRHR →read by rule
“Thyrotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07040137Spinocerebellar Degenerations · Japan3Active, not recruitingMar 31, 2027142
NCT02889302Spinocerebellar Degenerations · Japan3CompletedMar 2018203
NCT01970137Spinocerebellar Degenerations · Japan3CompletedOct 2014
NCT01970124Spinocerebellar Degenerations · Japan3CompletedMay 2015
NCT01970111Spinocerebellar Degenerations · Japan3CompletedJul 2015
NCT01970098Spinocerebellar Degenerations · Japan3CompletedJan 2015374
NCT01384435Spinocerebellar Degenerations · Japan2Completed200
NCT01004016Spinocerebellar Degenerations · Japan2Completed20
NCT00863538Spinocerebellar Degenerations · Japan2Completed40

How it is read

Names in the registry

  • “KPS-0373”, 8 entries
  • “KPS-0373, High dose”, 4 entries
  • “KPS-0373, Low dose”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.